Surge

Executive Summary

Surge (SurgeCare) is a San Francisco-based biotechnology company leveraging AI and advanced immune profiling to transform complex biological data into actionable clinical insights, initially targeting surgery, trauma, and infection. Founded in 2020, the company aims to decrypt the immune system to enable precision health through early detection of immune signatures that guide personalized patient care. Despite being in early stages with no disclosed funding or product pipelines, Surge operates in a high-growth area at the intersection of AI and immunology, addressing critical needs in acute care settings. The company's platform has the potential to improve clinical decision-making and outcomes, but it faces significant validation and commercialization hurdles typical of early-stage biotechs. Conviction is moderate given the lack of public data, but the space and technology are promising.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Publication of Proof-of-Concept Study in Peer-Reviewed Journal50% success
• Q2 2027Partnership with Major Hospital System for Pilot Program40% success